Shifting Goalposts For Vaccine Cos As Lambda Variant Rears Head
Multiple Vaccines Show Delta Efficacy
Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?
You may also be interested in...
With an emergency approval, Zydus Cadila has commercialized the world’s first plasmid DNA vaccine for human use and the first COVID-19 vaccine for use in adolescents in India. Will efficacy against the Delta variant help tide over hesitancy towards a new technology or a lack of publicly published data hamper acceptance?
While a Star Health study found high hospitalization costs for COVID-19 patients in India, those vaccinated paid 24% less and faced 81% lower mortality risk. However, insurers are unlikely to offer lower premiums to those vaccinated, even as the prospects for an overall hike remain uncertain, say experts.
As coronavirus variants keep emerging, global herd immunity is unlikely, says Steven Jones, one of the developers of the first Ebola vaccine. In a wide-ranging discussion with McKinsey, he and other experts weighed in on ways to live with COVID-19, which is expected to soon become endemic.